BioMimetic Therapeutics Introduces New Bone Graft Substitute

BioMimetic Therapeutics introduced the Augmatrix Biocomposite Bone Graft, a new bone graft substitute product line composed of carbonate-apatite and Type 1 collagen, according to a company news release.

Advertisement

Augmatrix is designed for use with bone marrow aspirate and has been cleared for use in multiple environments, such as fracture repair and general bone void filling procedures.


Sign up for our FREE Orthopedic E-Weekly for more coverage like this sent to your inbox!

Related Articles on Orthopedic Implants:
Hospital for Special Surgery Research Analyzes Hip Implant Failures

Wright Medical Group Receives FDA Clearance for Patient-Specific Total Ankle Replacement

43 Orthopedic & Spine Devices Receive FDA 510(k) Clearance in January

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

  • From new technology acquisitions to regulatory clearances to leadership changes, here are 20 developments and updates from the biggest players…

  • SurGenTec’s ION-C earned FDA 510(k) clearance for ION-C navigation instruments with the ION-C posterior cervical facet fixation implant, according to…

  • VB Spine has made big pushes into the spine medtech space so far in 2026, including global expansions. Six headlines…

Advertisement

Comments are closed.